KOL KNOCKOUTTM: Cataract Edition | Aligning Patient Preferen -

KOL KNOCKOUT Cataract Edition Aligning Patient Preferences and Ocular Characteristics for Optimal IOL Matchmaking Round 2

Media formats available:

Details

Presenters

Overview
This popular CME program is a fun and exciting game show-style quiz competition that features key opinion leaders (KOLs) as contestants. Hosted by Program Chair Blake K. Williamson, MD, MPH, MS, the second of three rounds features Sumitra Khandelwal, MD; R. Luke Rebenitsch, MD; and Bennett Walton, MD, MBA, as contestants.
Dr. Williamson will present complex cataract surgery case studies and the KOLs will weigh in on their preferred treatment option, leaving the audience to vote on the winner!
There will be learning, laughter, and only one KOL left standing!
This activity is supported by an independent educational grant from Alcon.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Explain the importance of understanding patient goals, preferences, and lifestyle before cataract surgery
- Discuss available IOL delivery systems and their potential effect on the efficiency and safety of cataract surgery
- Identify the advantages and disadvantages of current and emerging advanced technology IOLs and summarize the latest data on potential outcomes achieved with different IOL types
- Develop personalized treatment plans and match the most appropriate IOL to each patient, based on their unique preferences, personality, and ocular characteristics
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Blake K. Williamson, MD, MPH, MS
Managing Partner
Williamson Eye Center and
Outpatient Surgery Center for Sight
Baton Rouge, LA

Sumitra Khandelwal, MD
Professor of Ophthalmology
Medical Director, Lions Eye Bank of Texas
Baylor College of Medicine
Houston, TX

R. Luke Rebenitsch, MD
Medical Director
ClearSight LASIK/43 Vision
Oklahoma City, OK

Bennett Walton, MD, MBA
Bennett Walton Vision
Houston, TX

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Blake K. Williamson, MD, MPH, MS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, BioTissue, Carl Zeiss Meditec, Diopsys, Eyevance, Glaukos, Johnson & Johnson Vision, New World Medical, Omeros, Shire, Sight Sciences, and Sun Pharma. Speaker’s Bureau: AbbVie, Allergan, Glaukos, New World Medical, and TearLab.
Sumitra Khandelwal, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Carl Zeiss Meditec, and Johnson & Johnson Vision.
R. Luke Rebenitsch, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec, RxSight, and STAAR Surgical. Shareholder: OSRx Pharmaceuticals. Speaker's Bureau: Carl Zeiss Meditec, RxSight, and STAAR Surgical.
Bennett Walton, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Alcon, Allergan, Bausch + Lomb, BVI, Bruder Healthcare Company, Carl Ziess Meditec, Lensar, RxSight, STAAR Surgical, and Tarsus Pharmaceuticals. Grant/Research Support: Alcon, Avedro, BVI, Lensar, and RxSight. Speaker's Bureau: Alcon, Carl Zeiss Meditec, and STAAR Surgical.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Alcon.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 09/26/2023
Expiration Date: 10/06/2023